We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02673593
First Posted: February 4, 2016
Last Update Posted: February 4, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
DS Biopharma
  Purpose

The purpose of the study is to investigate the safety, pharmacokinetics and food effect of DS102 (up to 2000mg single and multiple daily doses) and placebo in healthy participants.

DS102 capsules will be orally administered for up to 4 weeks, and will be compared against placebo.

The study will enrol approximately 56 adult subjects.


Condition Intervention Phase
Healthy Drug: DS102 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Official Title: A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose Phase I Study to Assess the Safety, Pharmacokinetics and Effect of Food on Orally Administered DS102 in Healthy Subjects

Further study details as provided by DS Biopharma:

Primary Outcome Measures:
  • Safety (adverse events, laboratory tests, vital signs, ECGs) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall safety of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by Cmax) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by tmax) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by AUC0-inf) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by AUClast) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by CL/F) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by Vz/F ) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by t½) of DS102 administered as a single dose [ Time Frame: 14 days ]
    Phase I study - Overall PK of product in first in man study

  • Safety (adverse events, laboratory tests, vital signs, ECGs) of DS102 administered as a multiple dose for 28 days [ Time Frame: 42 days ]
    Phase I study - Overall safety of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by Cmax) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by tmax) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by AUC0-inf) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by AUClast) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by CL/F) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by Vz/F) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by AUC 0-24) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by Css) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study

  • Pharmacokinetics (Plasma concentrations assessed by t½) of DS102 administered as a multiple dose [ Time Frame: 42 days ]
    Phase I study - Overall PK of product in first in man study


Enrollment: 57
Study Start Date: July 2015
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Taken orally as a single dose (Cohorts 1 - 4) Taken orally as a multiple daily dose for 28 days (Cohorts 5 - 7)
Drug: Placebo
Experimental: DS102 100mg Single Dose
Taken orally once by Cohort 1
Drug: DS102
Experimental: DS102 500mg Single Dose
Single Dose taken orally on three separate occasions by Cohort 2 (second and third dose assessing food effect)
Drug: DS102
Experimental: DS102 1000mg Single Dose
Taken orally once by Cohort 3
Drug: DS102
Experimental: DS102 2000mg Single Dose
Taken orally once by Cohort 4
Drug: DS102
Experimental: DS102 500mg Multiple Dose
Taken orally once a day for 28 days by Cohort 5
Drug: DS102
Experimental: DS102 1000mg Multiple Dose
Taken orally once a day for 28 days by Cohort 6
Drug: DS102
Experimental: DS102 2000mg Multiple Dose
Taken orally once a day for 28 days by Cohort 7
Drug: DS102

Detailed Description:

There will be 7 cohorts enrolled, each consisting of 8 subjects.

Cohorts 1 - 4 will be orally administered up to 2000mg single doses of DS102 on Day 1.

Cohorts 5 - 7 will be orally administered up to 2000mg multiple daily doses of DS102 for 28 days.

The primary objective is to assess the safety and plasma pharmacokinetics of single and multiple daily oral doses of DS102.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is male or female and is aged between 18 and 45 years inclusive.
  • Subject's body mass index (BMI) is between 18.0 and 30.0 kg/m2 inclusive.
  • Subject is a non-smoker, has been a non-smoker for 3 months prior to screening and has a negative urine cotinine test at screening.

Exclusion Criteria:

  • Subject has had a clinically significant illness in the 4 weeks before screening.
  • Use of prescribed medication in the 2 weeks before dosing or over-the-counter preparations (including vitamins and supplements) for 1 week before dosing
  • Subject has a significant history of drug/solvent abuse, or a positive drugs of abuse (DOA) test at screening or Day -1.
  • Subject with a history of alcohol abuse in the opinion of the Investigator, or who currently drinks in excess of 28 units per week (males) or 21 units per week (females), whereby a unit consists of 10ml or 8mg of pure alcohol, or who have a positive alcohol urine test at screening or Day -1.
  • Subject has participated in any other clinical study with an investigational drug/device within 3 months before the first day of administration of study treatment.
  • Subject has a positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen or Hepatitis C antibodies at screening.
  • Subject has had a serious adverse reaction or significant hypersensitivity to any drug.
  • Subject has donated blood or blood products within 3 months before screening.
  • Subject has known hypersensitivity to any ingredients of the study treatment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02673593


Locations
Ireland
DS Biopharma Investigational Site
Belfast, Ireland
Sponsors and Collaborators
DS Biopharma
  More Information

Responsible Party: DS Biopharma
ClinicalTrials.gov Identifier: NCT02673593     History of Changes
Other Study ID Numbers: DS102A-01
First Submitted: January 21, 2016
First Posted: February 4, 2016
Last Update Posted: February 4, 2016
Last Verified: January 2016

Keywords provided by DS Biopharma:
Safety
Pharmacokinetics
Food Effect